Teladoc Health (NYSE:TDOC) Price Target Cut to $21.00

Teladoc Health (NYSE:TDOC - Get Free Report) had its price objective dropped by equities research analysts at Oppenheimer from $26.00 to $21.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has an "outperform" rating on the health services provider's stock. Oppenheimer's price target would suggest a potential upside of 61.41% from the company's previous close.

A number of other brokerages have also commented on TDOC. DA Davidson decreased their price target on shares of Teladoc Health from $22.00 to $18.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 21st. Barclays decreased their price target on shares of Teladoc Health from $25.00 to $20.00 and set an "overweight" rating on the stock in a research note on Friday. Truist Financial decreased their price target on shares of Teladoc Health from $23.00 to $17.00 and set a "hold" rating on the stock in a research note on Wednesday, March 6th. TD Cowen decreased their price target on shares of Teladoc Health from $16.00 to $15.00 and set a "hold" rating on the stock in a research note on Friday. Finally, Royal Bank of Canada decreased their target price on shares of Teladoc Health from $25.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday. Eleven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $19.67.

Teladoc Health Stock Down 2.4 %

NYSE:TDOC traded down $0.32 on Friday, hitting $13.01. 7,695,552 shares of the company's stock were exchanged, compared to its average volume of 4,798,968. The firm has a 50-day moving average price of $15.01 and a 200-day moving average price of $17.77. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.54 and a quick ratio of 3.47. Teladoc Health has a 52 week low of $12.65 and a 52 week high of $30.41. The company has a market cap of $2.20 billion, a P/E ratio of -9.71 and a beta of 0.94.

Teladoc Health (NYSE:TDOC - Get Free Report) last released its quarterly earnings data on Thursday, April 25th. The health services provider reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.02). The firm had revenue of $646.13 million for the quarter, compared to analyst estimates of $637.31 million. Teladoc Health had a negative return on equity of 9.22% and a negative net margin of 8.47%. The firm's revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.37) earnings per share. As a group, analysts expect that Teladoc Health will post -1.07 EPS for the current fiscal year.

Insider Transactions at Teladoc Health

In other Teladoc Health news, EVP Andrew Turitz sold 6,190 shares of the company's stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $89,878.80. Following the completion of the transaction, the executive vice president now directly owns 39,429 shares in the company, valued at approximately $572,509.08. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Teladoc Health news, CEO Jason N. Gorevic sold 53,755 shares of the company's stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $780,522.60. Following the completion of the transaction, the chief executive officer now directly owns 653,073 shares in the company, valued at approximately $9,482,619.96. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Andrew Turitz sold 6,190 shares of the company's stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $89,878.80. Following the completion of the transaction, the executive vice president now owns 39,429 shares of the company's stock, valued at $572,509.08. The disclosure for this sale can be found here. In the last 90 days, insiders sold 135,441 shares of company stock valued at $2,038,251. Company insiders own 1.63% of the company's stock.

Institutional Investors Weigh In On Teladoc Health

Several large investors have recently modified their holdings of TDOC. ICA Group Wealth Management LLC acquired a new stake in shares of Teladoc Health during the fourth quarter worth $28,000. Hexagon Capital Partners LLC grew its holdings in Teladoc Health by 204.4% in the fourth quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider's stock worth $34,000 after purchasing an additional 1,065 shares during the period. RIA Advisory Group LLC acquired a new stake in Teladoc Health in the fourth quarter worth $36,000. GAMMA Investing LLC acquired a new stake in Teladoc Health in the fourth quarter worth $41,000. Finally, Principal Securities Inc. acquired a new stake in Teladoc Health in the fourth quarter worth $45,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.